Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711684 · ClinicalTrials.gov registry record · Phase 1
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01711684 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 6 participants.
The verdict
NCT01711684, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Melanoma is a life-threatening cancer which poses a significant health burden, especially when metastatic or spreading to areas other than the original tumor growth. Although various treatment options are currently available for melanoma, melanomas that have metastasized widely to the skin pose a significant clinical challenge as the available therapies have limited effect. This study proposes the use of a topically applied compound named diphenylcyclopropenone (DPCP) which has been shown to be effective in treating melanoma patients whose diseases have spread widely throughout the skin. DPCP works by having a patient's own immune system, which is usually used to fight infections, attack cancerous cells. This compound has commonly been used to treat other conditions such as warts and hair loss throughout the world for many years and is known to cause limited side effects. Altering a patient's own immune system through topical treatments has also been shown to benefit patients with other cancers that have metastasized to skin such as breast cancer. In this study, the investigators will use DPCP to treat cutaneous metastases of various cancers including melanoma. Our overall intention is to get a better understanding of effective immune responses in the skin that may mediate metastatic cancer regression or cure.
Interventions
- DRUG Diphenylcyclopropenone (DPCP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-10-16 |
| Est. Completion | 2015-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711684
The ClinicalTrials.gov registry entry for NCT01711684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diphenylcyclopropenone (DPCP) is the first listed.
NCT01711684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711684 about?
NCT01711684 is a clinical study titled "Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)". Melanoma is a life-threatening cancer which poses a significant health burden, especially when metastatic or spreading to areas other than the original tumor growth. Although various treatment options are currently available for melanoma, melanomas that have metastasized widely to the skin pose a si...
What is the current status of trial NCT01711684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-10-16. Estimated completion is 2015-06-22.
What interventions are being tested in trial NCT01711684?
The interventions under investigation include: Diphenylcyclopropenone (DPCP) (DRUG).
Who is sponsoring clinical trial NCT01711684?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.